Open Scanner

Specify a stock or a cryptocurrency in the search bar to get a summary

Internet Computer ICP
Bitcoin Cash BCH
Litecoin LTC
Field stub for analysis

Aridis Pharmaceuticals Inc

ARDS
Current price
0.06 USD -0.0049 USD (-7.55%)
Last closed 0.06 USD
Sector Healthcare
Industry Biotechnology
Exchange PINK
Capitalization 3 280 646 USD
Yield for 12 month -77.19 %
1Y
3Y
5Y
10Y
15Y
ARDS
21.11.2021 - 28.11.2021

Aridis Pharmaceuticals, Inc., a late-stage biopharmaceutical company, discovers and develops targeted immunotherapy using fully human monoclonal antibodies (mAb) to treat life-threatening infections. Its lead product candidate is AR-301, a fully human mAb of immunoglobulin 1 (IgG1) that has completed Phase III pivotal trials for the treatment of lung infections resulting from S. aureus alphatoxin, as well as developing AR-301 as an adjunctive therapy with SOC antibiotics to treat hospital acquired pneumonia and ventilator associated pneumonia. The company is also developing AR-320, a fully human IgG1 monoclonal antibody targeting S. aureus alpha toxin to treat infections caused by methicillin-resistant Staphylococcus aureus and methicillin-susceptible S. aureus; AR 501, an inhaled gallium citrate, which is in Phase 1/2a for the treatment of chronic lung infection associated with cystic fibrosis; and AR-101, a human IgM mAb, which is in Phase II clinical trials targeting Pseudomonas aeruginosa liposaccharides serotype O11. In addition, it develops AR-401 that is in preclinical stage to treat infections caused by Acinetobacter baumannii; AR-201, a fully human IgG1 mAb preclinical program for respiratory syncytial virus; and AR-701, a cocktail of two fully human immunoglobulin 1. The company was founded in 2003 and is headquartered in Los Gatos, California. Address: 983 University Avenue, Los Gatos, CA, United States, 95032

Check your investment idea

Find the best to beat the market
TSLA TSLA Tesla Motors
AAPL AAPL Apple
MSFT MSFT Microsoft

Analytics

WallStreet Target Price

2 USD

P/E ratio

Dividend Yield

Current Year

+19 250 000 USD

Last Year

+1 535 000 USD

Current Quarter

+417 000 USD

Last Quarter

+19 647 000 USD

Current Year

Last Year

+1 535 000 USD

Current Quarter

+417 000 USD

Last Quarter

+19 647 000 USD

Key Figures ARDS

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
EBITDA -347 000 USD
Operating Margin TTM -208.39 %
PE Ratio
Return On Assets TTM -4.4 %
PEG Ratio
Return On Equity TTM
Wall Street Target Price 2 USD
Revenue TTM 22 359 000 USD
Book Value -0.27 USD
Revenue Per Share TTM
Dividend Share
Quarterly Revenue Growth YOY 4.5 %
Dividend Yield
Gross Profit TTM -22 605 000 USD
Earnings per share -0.16 USD
Diluted Eps TTM -0.16 USD
Most Recent Quarter III 2023
Quarterly Earnings Growth YOY
Profit Margin -5.11 %

Dividend Analytics ARDS

Dividend growth over 5 years

Continuous growth

Payout Ratio 5 years average

Dividend History ARDS

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Forward Annual Dividend Rate
Ex Dividend Date
Forward Annual Dividend Yield
Last Split Factor
Payout Ratio
Last Split Date
Dividend Date

Stock Valuation ARDS

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
Forward PE 2.0606
Enterprise Value Revenue 0.4083
Price Sales TTM 0.143
Enterprise Value EBITDA -9.0631
Price Book MRQ 5.3976

Financials ARDS

1 year
3 years
5 years
10 years
15 years
Results 2019 Dynamics
* The data for this period has not yet been published

Technical indicators ARDS

For 52 weeks

0.05 USD 0.41 USD
50 Day MA 0.062 USD
Shares Short Prior Month 1 848 149
200 Day MA 0.073 USD
Short Ratio 0.22
Shares Short 2 003 965
Short Percent 6.8 %

Dynamics of changes in the value of assets

A

AUTR

0.050 USD Autris 0 (0%)
Detailed analytics
D

DADTF

0.0020 USD DataDot Technology Limited 0 (0%)
Detailed analytics
T

TEGY

0.030 USD TransAct Energy Corp 0 (0%)
Detailed analytics
N

NSGCF

0.034 USD Northstar Gold Corp 0 (0%)
Detailed analytics
C

CLCFF

0.025 USD Christina Lake Cannabis Corp 0 (0%)
Detailed analytics